Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- 1 October 2018
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 29 (Suppl 4), 192-237
- https://doi.org/10.1093/annonc/mdy275
Abstract
No abstract availableThis publication has 276 references indexed in Scilit:
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerThe New England Journal of Medicine, 2013
- Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancerAnnals of Oncology, 2013
- Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controlsHuman Molecular Genetics, 2012
- Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 studyThe Lancet Oncology, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisThe Lancet Oncology, 2011
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Postoperative Radiotherapy in the Treatment of Single Metastases to the BrainJama-Journal Of The American Medical Association, 1998
- Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgeryAnnals of Neurology, 1993